Trial Profile

A Phase I Study to Investigate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics(PK) of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIM 0272 (Primary)
Indications Cancer; Cervical cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Simcere Pharmaceutical Group

Most Recent Events

24 Oct 2023 Results (n=22; 25 Feb 2023) reporting safety data presented at the 48th European Society for Medical Oncology Congress
22 Apr 2022 New trial record
12 Jan 2022 According to a Simcere Pharmaceutical Group media release, IND of SCR-6920 has been accepted in China by NMPA for the treatment of advanced malignant tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com